RU2448096C2 - Диарилгидантоины - Google Patents
Диарилгидантоины Download PDFInfo
- Publication number
- RU2448096C2 RU2448096C2 RU2007146462/04A RU2007146462A RU2448096C2 RU 2448096 C2 RU2448096 C2 RU 2448096C2 RU 2007146462/04 A RU2007146462/04 A RU 2007146462/04A RU 2007146462 A RU2007146462 A RU 2007146462A RU 2448096 C2 RU2448096 C2 RU 2448096C2
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- hyperproliferative disorder
- composition according
- pharmaceutically acceptable
- treating
- Prior art date
Links
- 0 CC(C)(C(N(C1=S)c(cc2*)ccc2C#N)=O)N1c(cc1)cc(*)c1C(NC)=O Chemical compound CC(C)(C(N(C1=S)c(cc2*)ccc2C#N)=O)N1c(cc1)cc(*)c1C(NC)=O 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
- C07C331/16—Isothiocyanates
- C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
Настоящее изобретение относится к новым производным диарилгидантоина, а именно к соединениям формул [RD162], [RD162′] [RD162′′]. Также изобретение относится к фармацевтической композиции на основе указанных соединений, к способу лечения гиперпролиферативного заболевания, основанному на использовании указанных соединений. Технический результат: получены новые производные диарилтиогидантоина, обладающие полезной биологической активностью. 6 н. и 18 з.п. ф-лы, 29 ил., 11 табл., 60 пр.
Description
Claims (24)
5. Фармацевтическая композиция для лечения гиперпролиферативного нарушения, содержащая терапевтически эффективное количество соединения по любому из пп.1-4 или его фармацевтически приемлемой соли и фармацевтически приемлемые носитель или разбавитель.
6. Фармацевтическая композиция по п.5, которая имеет форму, выбранную из группы, состоящей из раствора, дисперсии, суспензии, порошка, капсулы, таблетки, пилюли, капсулы с замедленным выделением, таблетки с замедленным выделением, пилюли с замедленным выделением.
7. Фармацевтическая композиция по п.5, в которой соединение растворено.
8. Фармацевтическая композиция по п.5, дополнительно содержащая растворитель.
9. Фармацевтическая композиция по п.5, содержащая один или более диметилсульфоксид (ДМСО), полиэтиленгликоль (ПЕГ) и воду.
10. Фармацевтическая композиция по п.5, содержащая диметилсульфоксид (ДМСО), полиэтиленгликоль (ПЕГ) и воду.
11. Способ лечения гиперпролиферативного нарушения, включающий назначение фармацевтической композиции по п.5 субъекту, нуждающемуся в указанном лечении, осуществляя таким образом лечение гиперпролиферативного нарушения.
12. Способ по п.11, в котором композиция назначается с дозой соединения в диапазоне:
(a) около 0,001-100 мг на кг веса тела в день;
(b) около 0,01-100 мг на кг веса тела в день;
(c) около 0,1-10 мг на кг веса тела в день;
(d) около 1 мг на кг веса тела в день.
(a) около 0,001-100 мг на кг веса тела в день;
(b) около 0,01-100 мг на кг веса тела в день;
(c) около 0,1-10 мг на кг веса тела в день;
(d) около 1 мг на кг веса тела в день.
13. Способ по п.11, в котором композицию вводят внутривенной инъекцией, инъекцией в ткань, внутрибрюшинно, перорально или через нос.
14. Способ по п.11, в котором гиперпролиферативным нарушением является рак простаты.
15. Способ по п.14, в котором гиперпролиферативным нарушением является резистентный к гормонам рак простаты.
16. Фармацевтическая композиция для лечения гиперпролиферативного нарушения, содержащая терапевтически эффективное количество соединения по п.2 или его фармацевтически приемлемой соли, и фармацевтически приемлемый носитель или разбавитель.
17. Фармацевтическая композиция для лечения гиперпролиферативного нарушения, содержащая терапевтически эффективное количество соединения по п.3 или его фармацевтически приемлемой соли, и фармацевтически приемлемый носитель или разбавитель.
18. Фармацевтическая композиция для лечения гиперпролиферативного нарушения, содержащая терапевтически эффективное количество соединения по п.4 или его фармацевтически приемлемой соли, и фармацевтически приемлемый носитель или разбавитель.
19. Фармацевтическая композиция по п.5, в которой гиперпролиферативное нарушение представляет собой рак простаты.
20. Фармацевтическая композиция по п.5, в которой гиперпролиферативное нарушение представляет собой резистентный к гормонам рак простаты.
21. Фармацевтическая композиция по п.5, в которой гиперпролиферативное нарушение представляет собой чувствительный к гормонам рак простаты.
22. Фармацевтическая композиция по п.5, в которой гиперпролиферативное нарушение представляет собой доброкачественную гиперплазию простаты.
23. Фармацевтическая композиция по п.5, в которой гиперпролиферативное нарушение представляет собой рак молочной железы.
24. Фармацевтическая композиция по п.5, в которой гиперпролиферативное нарушение представляет собой рак яичников.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68083505P | 2005-05-13 | 2005-05-13 | |
US60/680,835 | 2005-05-13 | ||
US75035105P | 2005-12-15 | 2005-12-15 | |
US60/750,351 | 2005-12-15 | ||
US75655206P | 2006-01-06 | 2006-01-06 | |
US60/756,552 | 2006-01-06 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011152891A Division RU2638833C2 (ru) | 2005-05-13 | 2011-12-23 | Диарилгидантоины |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2007146462A RU2007146462A (ru) | 2009-06-20 |
RU2448096C2 true RU2448096C2 (ru) | 2012-04-20 |
RU2448096C3 RU2448096C3 (ru) | 2017-12-11 |
Family
ID=37431537
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007146462A RU2448096C3 (ru) | 2005-05-13 | 2006-03-29 | Диарилгидантоины |
RU2011152891A RU2638833C2 (ru) | 2005-05-13 | 2011-12-23 | Диарилгидантоины |
RU2017142159A RU2017142159A (ru) | 2005-05-13 | 2017-12-05 | Диарилгидантоины |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011152891A RU2638833C2 (ru) | 2005-05-13 | 2011-12-23 | Диарилгидантоины |
RU2017142159A RU2017142159A (ru) | 2005-05-13 | 2017-12-05 | Диарилгидантоины |
Country Status (28)
Country | Link |
---|---|
EP (5) | EP3106162A1 (ru) |
JP (11) | JP4644737B2 (ru) |
KR (11) | KR101515335B1 (ru) |
CN (5) | CN101222922B (ru) |
AT (1) | ATE541571T1 (ru) |
AU (1) | AU2006248109B2 (ru) |
BR (1) | BRPI0610359B8 (ru) |
CA (1) | CA2608436C (ru) |
CY (2) | CY1112798T1 (ru) |
DK (2) | DK1893196T4 (ru) |
ES (2) | ES2535179T3 (ru) |
HK (3) | HK1112856A1 (ru) |
HR (2) | HRP20120323T4 (ru) |
HU (1) | HUS1300076I1 (ru) |
IL (3) | IL187328A (ru) |
LU (1) | LU92338I2 (ru) |
ME (1) | ME01992B (ru) |
MX (4) | MX346924B (ru) |
NO (4) | NO339997B1 (ru) |
NZ (3) | NZ591119A (ru) |
PL (2) | PL1893196T5 (ru) |
PT (2) | PT2444085E (ru) |
RS (2) | RS53967B1 (ru) |
RU (3) | RU2448096C3 (ru) |
SG (1) | SG10201703816SA (ru) |
SI (2) | SI1893196T2 (ru) |
WO (1) | WO2006124118A1 (ru) |
ZA (2) | ZA200710870B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014062852A2 (en) * | 2012-10-16 | 2014-04-24 | Whitehead Institute For Biomedical Research | Thiohydantoin derivatives and uses thereof |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2299266A1 (en) | 2003-12-19 | 2011-03-23 | The Regents of the University of California | Methods and materials for assessing prostate cancer therapies |
AU2005232526B2 (en) | 2004-02-24 | 2011-06-23 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies and compounds |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
PT2444085E (pt) | 2005-05-13 | 2015-06-11 | Univ California | Compostos de diaril-hidantoínas como antagonistas do recetor androgénio para tratamento de cancro |
EP2656842B1 (en) | 2006-03-27 | 2016-08-10 | The Regents of The University of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
EP3020706A1 (en) * | 2006-03-29 | 2016-05-18 | The Regents Of The University Of California | Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder |
WO2008093838A1 (ja) * | 2007-02-01 | 2008-08-07 | Chugai Seiyaku Kabushiki Kaisha | スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用 |
US8461343B2 (en) | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
CA2966280A1 (en) * | 2007-10-26 | 2009-04-30 | The Regents Of The University Of California | Diarylhydantoin compounds |
CA2753425A1 (en) * | 2009-02-24 | 2010-09-02 | Medivation Prostate Therapeutics, Inc. | Specific diarylhydantoin and diarylthiohydantoin compounds |
CN101817787B (zh) * | 2009-02-26 | 2013-07-24 | 童友之 | 抗***癌的雄性激素受体拮抗剂 |
KR20120036842A (ko) * | 2009-05-12 | 2012-04-18 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4d7 |
WO2011029392A1 (en) * | 2009-09-10 | 2011-03-17 | Youzhi Tong | Androgen receptor antagonists and uses thereof |
TW201111378A (en) * | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
CN102481294A (zh) | 2009-09-11 | 2012-05-30 | 拜耳医药股份有限公司 | 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲 |
AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
MX2012006615A (es) | 2009-12-11 | 2012-10-05 | Autifony Therapeuticts Ltd | Derivados de imidazolidinodiona. |
PT3124481T (pt) | 2010-02-16 | 2018-06-18 | Aragon Pharmaceuticals Inc | Moduladores do receptor de androgénios e suas utilizações |
EP3329775B1 (en) | 2010-02-24 | 2021-04-21 | Medivation Prostate Therapeutics LLC | Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds |
RU2434851C1 (ru) * | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения |
AU2011340258C1 (en) | 2010-12-06 | 2016-10-20 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
BR112013023028B1 (pt) * | 2011-03-10 | 2021-09-21 | Suzhou Kintor Pharmaceuticals, Inc | Composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e formulação farmacêutica tópica |
KR101958177B1 (ko) | 2011-04-21 | 2019-03-15 | 오리온 코포레이션 | 안드로겐 수용체 조절성 카복스아미드 |
JP6008953B2 (ja) | 2011-06-07 | 2016-10-19 | アウトイフオンイ トヘラペウトイクス リミテッド | Kv3阻害剤としてのヒダントイン誘導体 |
EA028452B1 (ru) * | 2011-07-29 | 2017-11-30 | Медивейшн Простейт Терапьютикс, Инк. | Лечение рака молочной железы |
WO2013079964A1 (en) | 2011-11-30 | 2013-06-06 | Astrazeneca Ab | Combination treatment of cancer |
CN103159680A (zh) * | 2011-12-14 | 2013-06-19 | 爱美尼迪药物有限公司 | 咪唑二酮类化合物及其用途 |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
EP2852589B1 (en) | 2012-05-22 | 2021-04-28 | Autifony Therapeutics Limited | Triazoles as kv3 inhibitors |
JP2015517563A (ja) | 2012-05-22 | 2015-06-22 | アウトイフオンイ トヘラペウトイクス リミテッド | Kv3阻害剤としてのヒダントイン誘導体 |
DK2894151T3 (da) * | 2012-09-04 | 2021-01-11 | Shanghai hengrui pharmaceutical co ltd | Imidazolinderivater, fremgangsmåder til fremstilling deraf og anvendelse deraf i medicin |
CN109897004A (zh) * | 2012-09-11 | 2019-06-18 | 麦迪威森***医疗有限责任公司 | 恩杂鲁胺制剂 |
CA2884640A1 (en) * | 2012-09-11 | 2014-03-20 | Dr. Reddy's Laboratories Limited | Enzalutamide polymorphic forms and its preparation |
EA030128B1 (ru) | 2012-09-26 | 2018-06-29 | Арагон Фармасьютикалз, Инк. | Способ лечения неметастатического кастрационно-резистентного рака простаты |
CA2889756C (en) | 2012-10-26 | 2023-03-14 | Memorial Sloan-Kettering Cancer Center | Thiohydantoin compounds as androgen receptor modulators |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
RU2520134C1 (ru) * | 2013-02-27 | 2014-06-20 | Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") | Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения |
WO2014167428A2 (en) * | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
BR112015031155A2 (pt) | 2013-06-20 | 2017-07-25 | Bayer Cropscience Ag | derivados de sulfureto de arila e derivados de aril sulfóxido como acaricidas e inseticidas |
CN104341396A (zh) * | 2013-08-08 | 2015-02-11 | 上海医药集团股份有限公司 | 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用 |
WO2015042170A1 (en) | 2013-09-17 | 2015-03-26 | Wayne State University | Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds |
CA2921156A1 (en) * | 2013-09-19 | 2015-03-26 | Glaxosmithkline Llc | Combination drug therapy |
CN106543085A (zh) * | 2013-10-14 | 2017-03-29 | 杭州普晒医药科技有限公司 | 恩杂鲁胺的固态形式及其制备方法和用途 |
US20160251316A1 (en) | 2013-10-31 | 2016-09-01 | Sun Pharmaceutical Industries Limited | Process for the preparation of enzalutamide |
EP3083568A1 (en) | 2013-12-16 | 2016-10-26 | Sun Pharmaceutical Industries Ltd | Processes and intermediates for the preparation of enzalutamide |
US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
CN104803919A (zh) * | 2014-01-26 | 2015-07-29 | 上海医药工业研究院 | 用于制备恩杂鲁胺中间体的方法 |
US20170174635A1 (en) | 2014-02-13 | 2017-06-22 | Sun Pharmaceutical Industries Limited | Process for the preparation of enzalutamide |
CZ2014232A3 (cs) | 2014-04-07 | 2015-10-14 | Zentiva, K.S. | Způsob výroby enzalutamidu |
CN103896847B (zh) * | 2014-04-09 | 2016-01-20 | 沈江 | 一种非甾体类抗雄激素化合物及其制备方法和应用 |
CN103910679B (zh) * | 2014-04-23 | 2016-05-25 | 杭州新博思生物医药有限公司 | 一种恩杂鲁胺的制备方法 |
CN104003939B (zh) * | 2014-06-06 | 2017-07-07 | 山东大学 | 二芳基取代乙内酰硫脲类化合物及其制备方法与应用 |
CN104016924B (zh) * | 2014-06-16 | 2016-04-13 | 上海鼎雅药物化学科技有限公司 | 一种“一锅法”合成恩杂鲁胺的方法 |
WO2015196144A2 (en) | 2014-06-20 | 2015-12-23 | England Pamela M | Androgen receptor antagonists |
RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
EP3166931A4 (en) * | 2014-07-11 | 2018-05-09 | Shilpa Medicare Limited | An improved process for the preparation of enzalutamide |
EP3230471B1 (en) | 2014-12-12 | 2019-08-28 | Medivation Prostate Therapeutics LLC | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer |
CN104610111A (zh) * | 2014-12-26 | 2015-05-13 | 杭州和泽医药科技有限公司 | 一种4-异硫代氰酰基-2-(三氟甲基)苯甲腈的制备方法 |
CN105523958B (zh) * | 2015-01-13 | 2017-11-03 | 北京海步医药科技股份有限公司 | 一种制备二芳基硫代乙内酰脲衍生物关键中间体的方法 |
CN106187905B (zh) * | 2015-05-05 | 2020-02-21 | 北京海步医药科技股份有限公司 | 丁鲁他胺的结晶形式及其制备方法 |
ITUB20151204A1 (it) | 2015-05-28 | 2016-11-28 | Olon Spa | Procedimento per la preparazione di enzalutamide |
ITUB20151311A1 (it) * | 2015-05-28 | 2016-11-28 | Olon Spa | Procedimento per la preparazione di enzalutamide |
ITUB20151256A1 (it) | 2015-05-28 | 2016-11-28 | Olon Spa | Processo industriale per la preparazione di enzalutamide |
WO2016194813A1 (ja) * | 2015-05-29 | 2016-12-08 | アステラス製薬株式会社 | エンザルタミド結晶形の製造方法 |
CN107001284B (zh) * | 2015-09-10 | 2019-11-22 | 江苏恒瑞医药股份有限公司 | 一种雄性激素受体抑制剂的结晶形式及其制备方法 |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
EP3481394A1 (en) * | 2016-07-08 | 2019-05-15 | Janssen Pharmaceutica N.V. | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
WO2018108147A1 (zh) | 2016-12-16 | 2018-06-21 | 康朴生物医药技术(上海)有限公司 | 一种组合、其应用及治疗方法 |
CN110573153B (zh) | 2017-04-28 | 2023-04-04 | 安斯泰来制药有限公司 | 含有恩杂鲁胺的口服给药用药物组合物 |
US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
US10513504B2 (en) | 2018-03-08 | 2019-12-24 | Apotex Inc. | Processes for the preparation of apalutamide and intermediates thereof |
CZ2018234A3 (cs) | 2018-05-21 | 2019-12-04 | Zentiva Ks | Zvýšení rozpustnosti a biodostupnosti enzalutamidu |
CN108976171B (zh) * | 2018-08-27 | 2020-06-16 | 长沙泽达医药科技有限公司 | 化合物、组合物及其在药物制备中的用途 |
EP3876929A1 (en) | 2018-11-05 | 2021-09-15 | Pfizer Inc. | Combination for treating cancer |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US11292782B2 (en) | 2018-11-30 | 2022-04-05 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
CN109796437B (zh) * | 2019-02-26 | 2021-08-24 | 上海健康医学院 | 具有ar和hdac双重抑制作用的乙内酰脲类和乙内酰硫脲类化合物及用途 |
CA3143111A1 (en) | 2019-06-27 | 2020-12-30 | Synthon B.V. | Process for preparation of enzalutamide |
CN110452166A (zh) * | 2019-09-06 | 2019-11-15 | 浙江朗华制药有限公司 | 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法 |
EP4037659A1 (en) | 2019-10-03 | 2022-08-10 | Synthon BV | Pharmaceutical composition comprising enzalutamide |
WO2021240206A1 (en) | 2020-05-24 | 2021-12-02 | Lotus International Pte. Ltd. | Enzalutamide formulation |
US20240000783A1 (en) | 2020-08-13 | 2024-01-04 | Pfizer Inc. | Combination therapy |
WO2022123310A1 (en) | 2020-12-11 | 2022-06-16 | Ildong Pharmaceutical Co., Ltd. | Novel compounds as androgen receptor and phosphodiesterase dual inhibitor |
WO2022200982A1 (en) | 2021-03-24 | 2022-09-29 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
EP4112603A1 (en) | 2021-06-29 | 2023-01-04 | Química Sintética, S.A. | Processes for the preparation of non-steroidal antiandrogens |
KR20230052759A (ko) | 2021-10-13 | 2023-04-20 | 주식회사 엘지에너지솔루션 | 배터리 충방전 프로파일 분석 방법 및 배터리 충방전 프로파일 분석 장치 |
CN114181155A (zh) * | 2021-12-21 | 2022-03-15 | 上海朝晖药业有限公司 | 碘-恩杂鲁胺及其制备方法及其应用 |
CN117164520A (zh) * | 2022-01-28 | 2023-12-05 | 南京思聚生物医药有限公司 | 一种局部作用的雄激素受体拮抗剂及其应用 |
KR20230170859A (ko) | 2022-06-11 | 2023-12-19 | 이태영 | 패스트칫솔 |
WO2024074959A1 (en) | 2022-10-02 | 2024-04-11 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
EP4374853A1 (en) | 2022-11-22 | 2024-05-29 | Lotus Pharmaceutical Co., Ltd. | Solid formulation of enzalutamide |
CN115850186B (zh) * | 2023-02-07 | 2024-04-09 | 长沙泽达医药科技有限公司 | 一种乙撑硫脲衍生物的晶型及用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2329276A1 (fr) | 1975-10-29 | 1977-05-27 | Roussel Uclaf | Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant |
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
FR2671348B1 (fr) | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
FR2693461B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
US5411981A (en) * | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
FR2694290B1 (fr) | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
FR2715402B1 (fr) * | 1994-01-05 | 1996-10-04 | Roussel Uclaf | Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
CA2181358A1 (en) † | 1994-01-21 | 1995-07-27 | Nancy M. Gray | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
FR2725206B1 (fr) | 1994-09-29 | 1996-12-06 | Roussel Uclaf | Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
FR2741342B1 (fr) | 1995-11-22 | 1998-02-06 | Roussel Uclaf | Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques |
US6673799B1 (en) | 1998-09-22 | 2004-01-06 | Yamanouchi Pharmaceutical Co. Ltd. | Cyanophenyl derivative |
US6861432B2 (en) | 2001-11-23 | 2005-03-01 | Schering Aktiengesellschaft | Piperazine derivatives that destabilize androgen receptors |
CA2500977A1 (en) | 2002-10-04 | 2004-04-15 | Laboratoires Fournier S.A. | 2-thiohydantoine derivative compounds and use thereof in therapeutics |
FR2850652B1 (fr) | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
US20050005529A1 (en) | 2003-07-10 | 2005-01-13 | David Brault | Lighting system for a greenhouse |
AU2005232526B2 (en) * | 2004-02-24 | 2011-06-23 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies and compounds |
WO2006028226A1 (ja) | 2004-09-09 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | 新規イミダゾリジン誘導体およびその用途 |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
PT2444085E (pt) * | 2005-05-13 | 2015-06-11 | Univ California | Compostos de diaril-hidantoínas como antagonistas do recetor androgénio para tratamento de cancro |
-
2006
- 2006-03-29 PT PT111844015T patent/PT2444085E/pt unknown
- 2006-03-29 CN CN2006800255451A patent/CN101222922B/zh active Active
- 2006-03-29 AU AU2006248109A patent/AU2006248109B2/en active Active
- 2006-03-29 KR KR1020147003529A patent/KR101515335B1/ko active IP Right Grant
- 2006-03-29 KR KR1020197025316A patent/KR102324567B1/ko active IP Right Grant
- 2006-03-29 DK DK06748863.5T patent/DK1893196T4/en active
- 2006-03-29 CN CN2012100273781A patent/CN102584712A/zh active Pending
- 2006-03-29 KR KR1020177025842A patent/KR102020721B1/ko active IP Right Grant
- 2006-03-29 DK DK11184401T patent/DK2444085T3/en active
- 2006-03-29 EP EP16171151.0A patent/EP3106162A1/en not_active Withdrawn
- 2006-03-29 CN CN202211664795.7A patent/CN116003328A/zh active Pending
- 2006-03-29 ES ES11184401.5T patent/ES2535179T3/es active Active
- 2006-03-29 PL PL06748863T patent/PL1893196T5/pl unknown
- 2006-03-29 PT PT06748863T patent/PT1893196E/pt unknown
- 2006-03-29 WO PCT/US2006/011417 patent/WO2006124118A1/en active Application Filing
- 2006-03-29 EP EP12193684A patent/EP2561871A1/en not_active Withdrawn
- 2006-03-29 KR KR1020077029188A patent/KR101169832B1/ko active IP Right Grant
- 2006-03-29 MX MX2015003843A patent/MX346924B/es unknown
- 2006-03-29 EP EP11184401.5A patent/EP2444085B1/en not_active Revoked
- 2006-03-29 NZ NZ591119A patent/NZ591119A/xx unknown
- 2006-03-29 KR KR1020137012351A patent/KR101431407B1/ko active IP Right Grant
- 2006-03-29 JP JP2008511114A patent/JP4644737B2/ja active Active
- 2006-03-29 MX MX2007014132A patent/MX2007014132A/es active IP Right Grant
- 2006-03-29 RS RS20150269A patent/RS53967B1/en unknown
- 2006-03-29 BR BRPI0610359A patent/BRPI0610359B8/pt active IP Right Grant
- 2006-03-29 RS RS20120154A patent/RS52274B2/sr unknown
- 2006-03-29 KR KR1020147029832A patent/KR101579701B1/ko active IP Right Grant
- 2006-03-29 SI SI200631309T patent/SI1893196T2/sl unknown
- 2006-03-29 KR KR1020117007291A patent/KR101332889B1/ko active IP Right Grant
- 2006-03-29 ES ES06748863.5T patent/ES2378778T5/es active Active
- 2006-03-29 RU RU2007146462A patent/RU2448096C3/ru active
- 2006-03-29 AT AT06748863T patent/ATE541571T1/de active
- 2006-03-29 EP EP21193326.2A patent/EP3970721A1/en active Pending
- 2006-03-29 NZ NZ564223A patent/NZ564223A/en unknown
- 2006-03-29 CN CN201510296329.1A patent/CN105037273B/zh active Active
- 2006-03-29 SI SI200631926T patent/SI2444085T1/sl unknown
- 2006-03-29 KR KR1020127019589A patent/KR101332924B1/ko active IP Right Grant
- 2006-03-29 KR KR1020227045048A patent/KR20230003445A/ko not_active Application Discontinuation
- 2006-03-29 ME MEP-2012-154A patent/ME01992B/me unknown
- 2006-03-29 EP EP06748863.5A patent/EP1893196B2/en active Active
- 2006-03-29 PL PL11184401T patent/PL2444085T3/pl unknown
- 2006-03-29 CA CA2608436A patent/CA2608436C/en active Active
- 2006-03-29 NZ NZ710355A patent/NZ710355A/en unknown
- 2006-03-29 KR KR1020157019319A patent/KR101782236B1/ko active IP Right Grant
- 2006-03-29 SG SG10201703816SA patent/SG10201703816SA/en unknown
- 2006-03-29 KR KR1020217035915A patent/KR102481886B1/ko active IP Right Grant
- 2006-03-29 CN CN201910163070.1A patent/CN110003114B/zh active Active
-
2007
- 2007-11-12 MX MX2022009759A patent/MX2022009759A/es unknown
- 2007-11-12 IL IL187328A patent/IL187328A/en active Protection Beyond IP Right Term
- 2007-11-12 MX MX2019015200A patent/MX2019015200A/es unknown
- 2007-12-12 NO NO20076401A patent/NO339997B1/no active Protection Beyond IP Right Term
- 2007-12-13 ZA ZA2007/10870A patent/ZA200710870B/en unknown
-
2008
- 2008-07-28 HK HK08108334.0A patent/HK1112856A1/xx active IP Right Maintenance
-
2010
- 2010-10-22 JP JP2010237937A patent/JP5138753B2/ja active Active
-
2011
- 2011-12-23 RU RU2011152891A patent/RU2638833C2/ru active
-
2012
- 2012-03-12 ZA ZA2012/01793A patent/ZA201201793B/en unknown
- 2012-04-12 HR HRP20120323TT patent/HRP20120323T4/hr unknown
- 2012-04-18 CY CY20121100367T patent/CY1112798T1/el unknown
- 2012-07-30 JP JP2012168904A patent/JP5150780B2/ja active Active
- 2012-07-30 JP JP2012168905A patent/JP2012211190A/ja not_active Withdrawn
- 2012-10-12 HK HK12110076.2A patent/HK1169321A1/xx not_active IP Right Cessation
-
2013
- 2013-12-16 CY CY2013047C patent/CY2013047I2/el unknown
- 2013-12-17 LU LU92338C patent/LU92338I2/xx unknown
- 2013-12-17 HU HUS1300076C patent/HUS1300076I1/hu unknown
-
2015
- 2015-03-02 JP JP2015039980A patent/JP6013535B2/ja active Active
- 2015-04-21 HR HRP20150437TT patent/HRP20150437T1/hr unknown
-
2016
- 2016-01-28 IL IL243812A patent/IL243812A0/en unknown
- 2016-05-05 HK HK16105142.8A patent/HK1217103A1/zh unknown
- 2016-07-28 JP JP2016148183A patent/JP2016183200A/ja not_active Withdrawn
- 2016-12-15 NO NO20161996A patent/NO342490B1/no unknown
-
2017
- 2017-05-04 NO NO2017019C patent/NO2017019I1/no unknown
- 2017-12-05 RU RU2017142159A patent/RU2017142159A/ru unknown
-
2018
- 2018-02-13 NO NO20180225A patent/NO20180225A1/no unknown
- 2018-03-06 JP JP2018039424A patent/JP2018100292A/ja not_active Withdrawn
- 2018-04-23 IL IL258880A patent/IL258880A/en unknown
-
2019
- 2019-07-22 JP JP2019134558A patent/JP2019218352A/ja active Pending
-
2020
- 2020-11-11 JP JP2020187901A patent/JP2021035970A/ja not_active Withdrawn
-
2022
- 2022-04-25 JP JP2022071531A patent/JP2022101657A/ja active Pending
-
2023
- 2023-03-17 JP JP2023043191A patent/JP2023075313A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014062852A2 (en) * | 2012-10-16 | 2014-04-24 | Whitehead Institute For Biomedical Research | Thiohydantoin derivatives and uses thereof |
WO2014062852A3 (en) * | 2012-10-16 | 2014-06-19 | Whitehead Institute For Biomedical Research | Thiohydantoin derivatives and uses thereof |
US9944607B2 (en) | 2012-10-16 | 2018-04-17 | Whitehead Institute For Biomedical Research | Thiohydantoin derivatives and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2448096C2 (ru) | Диарилгидантоины | |
JP5826961B2 (ja) | 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン塩類 | |
CN103432133B (zh) | 核受体结合剂的用途 | |
RU2470642C2 (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
RU2012101095A (ru) | Диарилтиогидантоиновые соединения | |
CN107406417A (zh) | 4H‑吡咯并[3,2‑c]吡啶‑4‑酮衍生物 | |
CN106304835A (zh) | sGC刺激剂 | |
US20200223879A1 (en) | Pentaaza macrocyclic ring complexes possessing oral bioavailability | |
CN104530417A (zh) | 一种多官能化h型聚乙二醇衍生物及其制备方法 | |
JP2009541223A5 (ru) | ||
JP2008535902A5 (ru) | ||
ES2644870T3 (es) | Derivados de oxatiazina como agentes antibacterianos y anticancerígenos | |
CN108026026A (zh) | 作为化疗剂的β-取代的β-氨基酸和类似物及其应用 | |
KR20170081228A (ko) | 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법 | |
CN107922389A (zh) | 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮 | |
EA201270266A1 (ru) | Гетероциклические соединения | |
AU2013318672B2 (en) | Means and method for treating solid tumours | |
CN100526316C (zh) | 三氮唑并嘧啶类衍生物 | |
EA018079B1 (ru) | Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона | |
CN109922834B (zh) | 用于治疗癌症的卟啉化合物和组合物 | |
WO2015153814A1 (en) | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof | |
US20150250793A1 (en) | Bax agonist, compositions, and methods related thereto | |
US10266490B2 (en) | Radioprotector compounds | |
CN102741252A (zh) | 用作驱虫剂的螺吲哚啉化合物 | |
CN107043373A (zh) | 一种噁***类no供体型他汀衍生物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
QB4A | Licence on use of patent |
Free format text: SUB-LICENCE Effective date: 20161226 Free format text: LICENCE Effective date: 20161226 |